March 5, 2026- Thermo Fisher Scientific Inc. announced the opening of a new 8,000-square-meter distribution and labeling center supporting its immunodiagnostics business in Uppsala. The new center strengthens the company’s global supply chain for in vitro diagnostic tests used as an aid in the diagnosis of allergic and autoimmune diseases and is designed to support future growth in demand from healthcare systems worldwide.
Allergic and autoimmune diseases affect as many as two billion people globally, underscoring the need for accurate, reliable and accessible diagnostic solutions. From its immunodiagnostics hub in Uppsala, Thermo Fisher manufactures diagnostic tests that support clinicians in diagnosing and managing these conditions for millions of patients each year.
The distribution and labeling center represents an investment of $18 million (approximately 160 million SEK) in advanced infrastructure, automation and operational capabilities, and complements Thermo Fisher’s* existing research, development and manufacturing activities in Uppsala. It enhances the company’s ability to scale logistics operations, improve efficiency and ensure reliable delivery of high-quality diagnostic products to customers around the world.
The new distribution and labeling center features automated storage, scanning and labeling systems that improve efficiency, accuracy and traceability. Developed in line with Thermo Fisher’s global facility standards, the center incorporates energy-efficient design features.